

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HERAMED LIMITED
ABN	65 626 295 314

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	ANOUSHKA GUNGADIN
Date of last notice	28 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-
Date of change	12 February 2025
No. of securities held prior to change ANOUSHKA GUNGADIN	<ul style="list-style-type: none">- 850,000 unlisted options with an exercise price of \$0.1358 expiring 28/07/2027- 5,000,000 unlisted options with an exercise price of \$0.02 expiring 26/06/2028

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Number of Performance Rights	Vesting Condition	Exercise Date – Exercise no later than
	2,633,860	Share price* of 100% premium to share price at date of issue by 12 February 2026	18 months from vesting
	2,633,860	Share price* of 200% premium to share price at date of issue by 12 February 2027	18 months from vesting
	2,632,280	Share price* of 300% premium to share price at date of issue by 12 February 2030	18 months from vesting
	2,633,860	7,500 paid mums (accumulated) on HeraCARE platform by 30 June 2026	31 December 2027
	2,633,860	11,500 paid mums (accumulated) on HeraCARE platform by 30 June 2026	31 December 2027
	2,632,280	23,000 paid mums (accumulated) on HeraCARE platform by 30 June 2027	31 December 2028
*Share price for the purposes of satisfying the Vesting Condition for classes 1, 2 and 3 in the table above is measured on a 20 day volume weighted average price (VWAP).			
Number acquired	15,800,000		
Number disposed	-		
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil		
No. of securities held after change	<ul style="list-style-type: none"> - 850,000 unlisted options with an exercise price of \$0.1358 expiring 28/07/2027 - 5,000,000 unlisted options with an exercise price of \$0.02 expiring 26/06/2028 - 15,800,000 Performance Rights <ol style="list-style-type: none"> 1. 2,633,860 Share price* of 100% premium to share price at date of issue by 12 February 2026 expiring 18 months from vesting 2. 2,633,860 Share price* of 200% premium to share price at date of issue by 12 February 2027 expiring 18 months from vesting 3. 2,632,280 Share price* of 300% premium to share price at date of issue by 12 February 2030 expiring 18 months from vesting 4. 2,633,860 7,500 paid mums (accumulated) on HeraCARE platform by 30 June 2026 expiring 31 December 2027 		

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

	<p>5. 11,500 paid mums (accumulated) on HeraCARE platform by 30 June 2026 expiring 31 December 2027</p> <p>6. 23,000 paid mums (accumulated) on HeraCARE platform by 30 June 2027 expiring 31 December 2028</p> <p><i>*Share price for the purposes of satisfying the Vesting Condition for classes 1, 2 and 3 in the table above is measured on a 20 day volume weighted average price (VWAP).</i></p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Performance Rights approved at General Meeting on 19 December 2024.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
---	----

⁺ See chapter 19 for defined terms.

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.